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Abstract
Background: HER2/neu overexpression and/or amplification has been widely studied in a number of solid tumors,
primarily in the breast. In gynecologic neoplasms, determination of HER2/neu status has not been well studied as a
predictive biomarker in anti-HER2/neu treatment.
Methods: We systematically evaluated the HER2/neu reactions by immunohistochemistry and fluorescent in situ
hybridization in malignant gynecologic neoplasms as experienced in our institution.
Results: The HER2/neu overexpression or amplification occurred in 8 % of the cancers of the gynecological organs
in our series. Majority of the HER2/neu overexpression and/or amplification occurred in clear cell (27 %) and serous
(11 %) carcinomas. HER2/neu positivity was also seen in undifferentiated as well as in mixed clear cell and serous
carcinomas. Discordant IHC and FISH results (positive by FISH but not IHC) was seen in 2 cases. Majority of the
HER2/neu overexpression and/or amplification occurs in the endometrium rather than the ovary. Heterogeneity of
the HER2/neu by IHC staining was in < 2 % of the tumors in our series.
Conclusions: We recommend the HER2/neu studies on Müllerian carcinomas of clear cell, serous, and undifferentiated
types, particularly when they arise in the endometrium. Since there are some discordant IHC/FISH results, we also
propose performing the HER2/neu testing by FISH when the IHC score is less than 3 + .
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This work was presented as a poster at the annual meet-
ing of the United States and Canadian Academy of
Pathology (USCAP) in Boston Massachusetts in 2015 [1].
Background
Certain gynecologic cancers such as high grade endo-
metrial and ovarian cancers are a leading cause of mor-
bidity and mortality. Current treatment protocols for
both endometrial and ovarian based tumors are largely
organ specific and are not defined by histologic subtypes.
Certain histologic categories, however, have been associ-
ated with poor clinical outcomes. In the endometrium
(uterine corpus), serous and clear cell histologic subtypes
follow an aggressive clinical course as a result of their
high recurrence rate and relative resistance to conven-
tional chemotherapy [2]. In the ovary, clear cell ovarian
carcinoma has shown dismal response rates to the thera-
peutic agents [3]. In treatment of these tumors, targeting
the molecular pathway would be the next logical ap-
proach when the traditional chemotherapies fail or there
is a poor response.
The HER2/neu overexpression/amplification has been
widely studied in a number of solid tumors. When over-
expressed and/or amplified, there is a well-established
targeted therapy when the cancers occur in the breast,
esophagus, and stomach [4–6]. Overexpression of
HER2/neu has been previously reported in endometrial
serous, ovarian mucinous, and ovarian clear cell carcin-
omas [7–11]. Although the HER2/neu status in female
reproductive cancers has been investigated over the past
two decades, determination of the HER2/neu status has
not been well studied as a predictive biomarker for
* Correspondence: nmoatamed@mednet.ucla.edu
1Department of Pathology and Laboratory Medicine, David Geffen School of
Medicine at UCLA, 10833 Le Conte Avenue, BOX 951732, 1P-241 CHS, Los
Angeles, CA 90095-1732, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Woo et al. Diagnostic Pathology  (2016) 11:102 
DOI 10.1186/s13000-016-0553-8
response to anti-HER2/neu treatment in the gynecologic
cancers unlike in the breast and the digestive system. In
this study, we systematically evaluated the HER2/neu
status of the malignant gynecologic neoplasms, within
our institution, which can be used for its effectiveness in
the anti-HER2/neu therapies.
Methods
For the conduct of this study, an approval was obtained
from the Institutional Review Board at the David Geffen
School of Medicine at UCLA. The surgically excised
specimens which had been diagnosed with gynecologic
cancers (including endometrial, ovarian, and primary
peritoneal tumors) and had either immunohistochemical
(IHC) and/or fluorescence in-situ hybridization (FISH)
studies for the HER2/neu were selected for this study.
These cases were identified by a computer search of
the surgical pathology database (2005 to 2014) in our
institution. Hereupon, “HER2” is used for reference to
HER2/neu gene. Routinely, the HER2 tests by IHC
and/or FISH are not performed on all gynecological
neoplasms in our medical center. The tests are per-
formed at the request of the clinicians or determin-
ation by the pathologists only on the resected tumors.
Retrospective demographic and clinical data were col-
lected from a detailed review of medical records, including
operative notes and pathology reports. For all neo-
plastic lesions, when applicable, the FIGO (International
Federation of Gynecology and Obstetrics) and nuclear
grades were recorded according to the established cri-
teria [12].
Appropriate samples from the surgically excised speci-
mens were selected and fixed in 10 % neutral-buffered
formalin for at least 6 h and embedded in paraffin
blocks. Four-μm thick sections from the blocks were
stained with hematoxylin and eosin (H&E) according to
the established laboratory protocol. The HER2-IHC was
performed on the duplicate sections of the tissues using
the FDA-approved HercepTest™ kit (DAKO, Carpentaria,
CA, USA) containing appropriate positive and negative
controls [13]. The HER2-FISH assay was performed
on the tumor tissue sections using the FDA-approved
PathVysion™ HER2 DNA Probe Kit (Abbott Molecular
Inc., Des Plaines, IL) [14]. In all cases, at least an
area of 1 cm2 or greater of the tumor tissue was ana-
lyzed for assessing the HER2 reactions.
HER2 by IHC
Scores were assigned per the current American Society
of Clinical Oncology (ASCO)/College of American
Pathologists (CAP) guidelines for breast cancer [15].
The HER2 IHC-slides were re-reviewed by the two
pathologists (JW and NAM) and scored independently
according to the following algorithm [16, 17].
Score 0. No staining or incomplete membrane
staining that was faint/barely perceptible
in ≤ 10 % of tumor cells, indicating no
overexpression.
Score 1+. Incomplete membrane staining that was
faint/barely perceptible in > 10 % of tumor
cells, indicating no overexpression.
Score 2+. Complete circumferential moderately
intense membranous staining seen in
> 10 % of the tumor cells, indicating
equivocal overexpression.
Score 3+. Circumferential membrane staining that was
complete and intense involving > 10 % of
tumor cells, indicating overexpression of the
HER2 gene.
HER2 by FISH
In the assay, a ratio of HER2 to CEP17 (chromosome
enumerating probe-17) signals in 20 cells was used for
scoring the FISH test results. A HER2/CEP17 ratio of ≥ 2
was considered as positive for amplification of the HER2
gene. If the ratio was < 2, but the signals for HER2 copy
number per cell were ≥ 6, also the result was considered
positive per recommendations by the American Society
of Clinical Oncologists and the College of American
Pathologists [15, 18]. These recommendations, however,
have been for carcinomas of the breast and no such
recommendations are made for the HER2 FISH in the
cancers of other organs. Therefore, only the HER2/
CEP17 ratios of ≥ 2 are used to indicate a positive result
for non-breast cancers in our institution as used by
others [19, 20].
Study design
Cases with 3+ HER2 staining pattern of over expression
by IHC and/or the HER2/CEP17 ratio of ≥ 2 by FISH
were considered as positive for HER2 which are indi-
cated as such in the text and the tables. Cases with IHC
scores of 0 and 1+ and/or the HER2 ratios of < 2 by
FISH were classified as negative for HER2. An equivocal
IHC staining pattern of 2+ without a corresponding
FISH study was excluded from this study. The concord-
ance rate between the IHC and the FISH test results was
also recorded.
All the subjects were divided into 5 groups bases on
the histological malignancy types; Group I, clear cell
carcinoma; Group II, serous carcinoma; Group III, endo-
metrioid adenocarcinoma; Group IV, mixed surface epi-
thelial adenocarcinomas; and Group V, other malignant
neoplasms. For each group, pertinent findings were tab-
ulated including the HER2 reactions. In addition, each
case was evaluated for intratumoral heterogeneity of the
HER2 reaction by IHC staining as observed by Buza and
Hui [21]. The heterogeneity was defined as the presence
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of two-degree or more difference in staining scores in-
volving at least 5 % of the tumor cells [21].
Results
During the approximately 9-years period, a total of 125
gynecologic cases were identified per the inclusion cri-
teria which subsequently were evaluated for overexpres-
sion of the HER2 by IHC and/or amplification by FISH.
All cases had the IHC staining except for one (see
Group V below). Only 44 of the 125 patients had the
corresponding FISH results. Overall, 8 % (10/125) of the
gynecologic neoplasms had the HER2 overexpression/
amplification in this series. Discordant IHC and FISH re-
sults (positive by FISH but not by IHC) was seen in
20 % (2 of 10) of the HER2 positive cases.
Group I
This group was comprised of cases with a histological diag-
nosis of clear cell carcinoma. There were 11 subjects in this
group (Table 1). Patients’ ages ranged from 37 to 89 with a
median of 54 years old. Three (27.3 %) of these cases were
positive for HER2. Two of which had corresponding and
concordant FISH, while one had only overexpression by
IHC and FISH had not been performed (case # 3; Table 1).
One of the three positive HER2 cases was in the ovary and
the other two were in the endometrium which constituted
9.1 % and 18.2 % in this group respectively. An example of
a case with overexpression of the HER2 by IHC and ampli-
fication by FISH (case # 1; Table 1) is shown in Fig. 1.
Group II
This group was comprised of cases with a histological
diagnosis of serous carcinoma. There were 45 subjects in
this group (Table 2). Patients’ ages ranged from 32 to 83
with a median of 58 years old. Forty-four cases were of
high grade and only one case had a low grade serous
carcinoma (case # 11; Table 2). All cases in this group
Table 1 Group I, cases diagnosed with clear cell carcinomas
Case no. HER2/neu Primary site
IHC FISH Result
1 3+ 2.58 POS Ovary
2 2+ 2.89 POS Endometrium
3 3+ NP POS Endometrium
4 0 1.1 NEG Ovary
5 0 NP NEG Ovary
6 0 NP NEG Ovary
7 1+ NP NEG Ovary
8 0 NP NEG Endometrium
9 1+ NP NEG Endometrium
10 1+ NP NEG Endometrium
11 1+ NP NEG Endometrium
Bold data signify the positive results
IHC immunohistochemistry score, FISH fluorescence in-situ hybridization HER2/
CEP17 ratio, NP not performed, POS positive, NEG negative
Fig. 1 An example of a clear cell carcinoma, with the HER2
overexpression by IHC and amplification by FISH, is shown (case # 1;
Table 1). Panel (a) shows a photomicrograph of hematoxylin and eosin
stain (40× objective) of the tumor showing characteristic nuclear and
cytoplasmic morphology. The HER2 overexpression is displayed
showing a strong membrane staining by IHC (panel b, 40× objective)
and the HER2 gene (red signals) amplification by FISH (panel c)
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had the HER2 tested by IHC while 16 of them were ac-
companied by the FISH assay. Five (11.1 %) of these
cases were positive for the HER2, 2 by FISH (cases # 1–
2; Table 2), 2 by IHC and FISH (cases # 3–4; Table 2),
and 1 by IHC (case # 5; Table 2). The first two cases had
a score of 0 by IHC (cases # 1 and 2; Table 2) indicating
discordancy. In this Group, the positive HER2 cases
were 1 (2.2 %) in the ovary and 4 (8.9 %) in the endo-
metrium (Table 2). An example of a discordant case of
ovarian serous carcinoma (case # 1; Table 2) is shown in
Fig. 2. Four (# 3, 35, 44, & 45; Table 2) of the 16 cases
with corresponding FISH results had an IHC score of
2+. Of which only one showed the HER2 amplifica-
tion by FISH (case # 3; Table 2) while the other 3
did not (cases # 35, 44 & 45; Table 2).
Group III
This group was comprised of cases with a histological
diagnosis of endometrioid adenocarcinoma. There were
28 subjects in this group. Patients’ ages ranged from 31
to 86 with a median of 61.5 years old with varied FIGO
and nuclear grading from 1 to 3. All cases in this group
had the HER2 test by IHC while 6 of them were accom-
panied by the FISH assay. None (0.0 %) of these cases
were positive for the HER2 (Table 3).
Group IV
This group was comprised of cases with the histological
diagnosis of mixed surface epithelial adenocarcinomas.
The mixed surface epithelial carcinomas included clear
cell, serous, endometrioid, and mucinous types. There
were 26 subjects in this group. Patients’ ages ranged
from 30 to 78 with a median of 64 years old. Only one
(3.8 %) case, in this Group, was positive for the HER2
amplification with concordant IHC positivity which had
occurred in the endometrium (Case #1; Table 4). This
case had a histologic type of mixed clear cell and serous
carcinomas. Two (7.7 %) of the cases (cases # 7 & 20;
Table 4) in this group had intratumoral heterogeneity as
described above [21]. The patterns of the IHC staining
ranged from 0 to 3+ in both cases, where the 3+ reac-
tion was seen in less than 10 % of the tumor cells. One
of the examples of the heterogeneity of the reaction
(case # 20; Table 4) is shown in Fig. 3. Overall, these two
Table 2 Group II, cases diagnosed with serous carcinoma
Case no. HER2 amplification Primary site Histopathology diagnosis
IHC FISH Result Type FIGO Nuc
1 0 2.75 POS Ovary SCA 3 3
2 0 2.26 POS Endometrium SCA 3 3
3 2+ 5.16 POS Endometrium SCA 3 3
4 3+ 6.1 POS Endometrium SCA 3 3
5 3+ NP POS Endometrium SCA 3 3
6 0 1 NEG Fallopian Tube SCA 3 3
7 0 1 NEG Ovary SCA 3 3
8 0 1.03 NEG Ovary SCA 3 3
9 0 1.06 NEG Ovary SCA 3 3
10 0 1.4 NEG Ovary SCA 3 3
11 0 NP NEG Ovary SCA 1 1
12 0 NP NEG Ovary SCA 3 3
13 0 NP NEG Ovary SCA 3 3
14 0 NP NEG Ovary SCA 3 3
15 0 NP NEG Ovary SCA 3 3
16 0 NP NEG Ovary SCA 3 3
17 0 NP NEG Ovary SCA 3 3
18 0 NP NEG Ovary SCA 3 3
19 0 NP NEG Ovary SCA 3 3
20 0 NP NEG Ovary SCA 3 3
21 0 NP NEG Ovary SCA 3 3
22 1+ 1 NEG Ovary SCA 3 3
23 1+ 1 NEG Ovary SCA 3 3
24 1+ 1.2 NEG Ovary SCA 3 3
25 1+ NP NEG Ovary SCA 3 3
26 1+ NP NEG Ovary SCA 3 3
27 1+ NP NEG Ovary SCA 3 3
28 1+ NP NEG Ovary SCA 3 3
29 1+ NP NEG Ovary SCA 3 3
30 1+ NP NEG Ovary SCA 3 3
31 1+ NP NEG Ovary SCA 3 3
32 1+ NP NEG Ovary SCA 3 3
33 1+ NP NEG Ovary SCA 3 3
34 1+ NP NEG Ovary SCA 3 3
35 2+ 1.62 NEG Ovary SCA 3 3
36 0 1.08 NEG Peritoneum SCA 3 3
37 0 NP NEG Peritoneum SCA 3 3
38 0 NP NEG Peritoneum SCA 3 3
39 1+ NP NEG Peritoneum SCA 3 3
40 1+ NP NEG Peritoneum SCA 3 3
41 1+ NP NEG Endometrium SCA 3 3
42 1+ NP NEG Endometrium SCA 3 3
Table 2 Group II, cases diagnosed with serous carcinoma
(Continued)
43 1+ NP NEG Endometrium SCA 3 3
44 2+ 0.91 NEG Endometrium SCA 3 3
45 2+ 1.21 NEG Endometrium SCA 3 3
Bold data signify the positive results
IHC immunohistochemistry score, FISH fluorescence in-situ hybridization HER2/
CEP17 ratio, FIGO FIGO grade, Nuc nuclear grade, NP not performed, POS
positive, NEG negative, SCA serous carcinoma
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cases represented 1.6 % (2 of 125) heterogeneity in all
five groups.
Group V
This group was comprised of other neoplasms including
cases with histological diagnoses of undifferentiated
carcinoma of the endometrium, endocervical adenocar-
cinoma, endometrial stromal sarcoma (ESS), malignant
mixed müllerian tumor (MMMT), and yolk sac tumor of
the ovary. There were 15 subjects in this group. Patients’
ages ranged from 20 to 72 with a median of 54 years
old. Except for one (6.7 %), remaining 14 cases were
negative for the HER2 (Table 5). Of the 4 patients with a
diagnosis of undifferentiated carcinoma (UnDiff ), one
had the HER2 amplification (case #1; Table 5) with a
concordant IHC test.
All cases were further summarized in Table 6 showing
the numerical values as well as percentages of the HER2
positivity for each group. Among the cases with the
Fig. 2 An example of serous carcinoma, with discordant IHC
expression and FISH amplification (case # 1; Table 2), is shown. Note
the hematoxylin and eosin stain (panel a, 10× objective), negative
HER2 expression by IHC (panel b, 10× objective), and the HER2 gene
(red signals) amplification by FISH (panel c)
Table 3 Group III, cases diagnosed with endometrioid
adenocarcinomas
Case no. HER2/neu Primary site Histopathology diagnosis
IHC FISH Result Type FIGO Nuc
1 0 1.4 NEG Endometrium ENAdCA 2 3
2 0 1.15 NEG Endometrium ENAdCA 2 2
3 0 1.05 NEG Endometrium ENAdCA 2 2
4 1+ 0.98 NEG Endometrium ENAdCA 1 1
5 1+ 0.98 NEG Endometrium ENAdCA 1 2
6 0 NP NEG Fallopian Tube ENAdCA 2 2
7 1+ NP NEG Endometrium ENAdCA 1 2
8 1+ 1 NEG Endometrium ENAdCA 1 1
9 1+ NP NEG Endometrium ENAdCA 2 2
10 1+ NP NEG Ovary ENAdCA 3 3
11 0 NP NEG Endometrium ENAdCA 1 1
12 1+ NP NEG Endometrium ENAdCA 2 3
13 0 NP NEG Endometrium ENAdCA 2 2
14 0 NP NEG Ovary ENAdCA 3 3
15 1+ NP NEG Endometrium ENAdCA 2 2
16 1+ NP NEG Endometrium ENAdCA 2 2
17 1+ NP NEG Endometrium ENAdCA 3 2
18 0 NP NEG Ovary ENAdCA 3 3
19 1+ NP NEG Endometrium ENAdCA 1 2
20 0 NP NEG Endometrium ENAdCA 2 1
21 1+ NP NEG Endometrium ENAdCA 1 2
22 1+ NP NEG Endometrium ENAdCA 1 2
23 1+ NP NEG Endometrium ENAdCA 1 1
24 1+ NP NEG Endometrium ENAdCA 2 1
25 0 NP NEG Ovary ENAdCA 3 3
26 1+ NP NEG Endometrium ENAdCA 2 1
27 0 NP NEG Endometrium ENAdCA 2 2
28 0 NP NEG Ovary ENAdCA 3 3
IHC immunohistochemistry score, FISH fluorescence in-situ hybridization HER2/
CEP17 ratio, FIGO FIGO grade, Nuc nuclear grade, NP not performed, NEG nega-
tive, ENAdCA endometrioid adenocarcinoma
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HER2 positivity, clinical follow-ups were available only
for 4 patients.
In Table 7, the subjects were rearranged based on the
tumor primary sites or anatomical locations in each
group. In all five groups, there were 58 neoplasms of the
endometrium of which 8 (13.8 %) were HER2 positive.
There were 56 ovarian tumors of which 2 (3.6 %) were
positive for the HER2. The remaining 11 cases had neo-
plasms in locations other than endometrium and ovary
which had no HER2 positivity (Table 7). The percentages
of the positive HER2 cases, in each group, were recalcu-
lated for the respective sites of origin. Using this ar-
rangement, serous carcinomas (44.4 %) formed the
majority of the HER2 positivity followed by clear cell
(33.3 %), mixed epithelial (9.1 %) carcinomas, and other
neoplasms (10 %) of the endometrium. The only positive
HER2 case in Group V was the one of the four undiffer-
entiated carcinomas (Table 5). In all, 80 % (8 of 10) of
the HER2 positive neoplasms were in the endometrium
while 20 % positivity had occurred in the ovary. No posi-
tive HER2 reactions were observed in other sites
(Table 7). In addition, none of the endometrioid adeno-
carcinomas showed such a positivity.
The four cases with the positive HER2 tests were
treated with Transtuzumab followed by surgical removal.
They responded well initially measured by the imaging
studies.
Discussion
In our experience, the HER2 amplification or overex-
pression occurs in 8 % of the patients with cancer of the
female Müllerian organs. Therefore, it becomes imperative
Table 4 Group IV, cases diagnosed with mixed surface epithelial carcinomas
Case no. HER2/neu Primary site Histopathology diagnosis
IHC FISH Result Type FIGO Nuc
1 2+ 7.41 POS Endometrium CCCA + SCA 3 3
2 1+ 1.02 NEG Ovary CCCA + SCA 3 3
3 0 1.37 NEG Pelvic mass CCCA + SCA 3 3
4 0 NP NEG Ovary CCCA + SCA 3 3
5 0 NP NEG Ovary CCCA + SCA 3 3
6 0 NP NEG Ovary CCCA + SCA 3 3
7a 0–3+ 1.38 NEG Endometrium CCCA + SCA 3 3
8 1+ 0.93 NEG Endometrium CCCA + ENAdCA 3 3
9 1+ NP NEG Endometrium CCCA + ENAdCA 3 3
10 1+ NP NEG Endometrium CCCA + ENAdCA 3 3
11 0 NP NEG Ovary CCCA + ENAdCA 3 3
12 1+ NP NEG Ovary CCCA + ENAdCA 3 3
13 0 NP NEG Ovary CCCA + ENAdCA 3 3
14 0 NP NEG Endometrium SCA + ENAdCA 3 3
15 1+ NP NEG Ovary SCA + ENAdCA 3 3
16 0 NP NEG Peritoneum SCA + ENAdCA 3 3
17 0 NP NEG Endometrium SCA + ENAdCA 3 3
18 0 NP NEG Ovary SCA + ENAdCA 3 3
19 1+ 1.7 NEG Endometrium SCA + ENAdCA 3 3
20a 0–3+ 1.14 NEG Endometrium SCA + ENAdCA 3 3
21 0 NP NEG Ovary SCA + ENAdCA 3 3
22 1+ 1.2 NEG Endometrium SCA + ENAdCA 3 3
23 0 1.04 NEG Ovary SCA + ENAdCA 3 3
24 1+ 1 NEG Ovary SCA + ENAdCA 3 3
25 1+ 1 NEG Ovary SCA + ENAdCA +Mu 3 3
26 0 1 NEG Endometrium ENAdCA +Mu 1 1
Bold data signify the positive results
IHC immunohistochemistry score, FISH fluorescence in-situ hybridization HER2/CEP17 ratio, FIGO FIGO grade, Nuc nuclear grade, NP not performed, POS positive,
NEG negative, CCCA clear cell carcinoma, SCA serous carcinoma, ENAdCA endometrioid adenocarcinoma, Mu mucinous adenocarcinoma
a Denotes intratumoral heterogeneity of HER2 reaction
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to test the cancer tissues for overexpression of the HER2
for its potential therapeutic impact. When all the anatom-
ical sites are considered, majority of the HER2 overexpres-
sion and/or amplification occur in clear cell carcinomas
(Tables 1 and 7) at a rate of greater than 27 %. The next
tumor type is serous carcinoma which has a rate of 11 %
of the HER2 overexpression or amplification (Tables 2
and 7). When stratified by the tumor primary sites
(Table 7), serous carcinoma of the endometrium has the
highest incidence of the HER2 positivity (44.4 %) which is
in agreement with other studies reporting similar findings
[19, 21–26]. In general, 80 % of the tumors with the HER2
overexpression/amplification occur in the endometrium
and 20 % in the ovary. It appears that undifferentiated car-
cinomas may also exhibit similar HER2 positivity (Table 5)
which is contrary to a published study [27].
Amplification or overexpression of the HER2 in
these tumor types, as part of type II endometrial
adenocarcinomas, has also been reported by other investi-
gators [8]. Unlike other studies, this series contains all the
female Müllerian organs. In this comprehensive systematic
evaluation, it becomes clear that the majority of the HER2
amplification occurs in the endometrium rather than the
ovary while no such amplification occurs in other organs
or sites in this series.
Heterogeneity of the HER2 by IHC staining was seen
in less than 2 % of the cases in our series while a higher
percentage has been reported by others. Buza et al. have
shown that 35 % of the endometrial serous carcinomas
had the HER2 overexpression and/or gene amplification
Fig. 3 An example of a case with intratumoral HER2 heterogeneity
(case # 20; Table 4) is shown with its hematoxylin and eosin stain
counterpart (panel a, 10× objective). The HER2 by IHC shows a
strong reaction in the upper and a weak or no reaction in the lower
parts of the photomicrograph (panel b, 10× objective). The inset in
panel B shows strong cell membrane staining of the HER2 by IHC in
the overexpressed part of the tumor (40× objective)
Table 5 Group V, cases diagnosed with other malignant
neoplasms
Case no. HER2/neu Primary site Histopathology diagnosis
IHC FISH Result Type FIGO Nuc
1 3+ 3.5 POS Endometrium UnDiff 3 3
2 0 NP NEG Endometrium UnDiff 3 3
3 1+ NP NEG Endometrium UnDiff 3 3
4 NP 1 NEG Endometrium UnDiff 3 3
5 0 NP NEG Ovary MMMT NA NA
6 0 1.54 NEG Endometrium MMMT NA NA
7 0 NP NEG Endometrium MMMT NA NA
8 1+ NP NEG Endometrium MMMT NA NA
9 1+ NP NEG Pelvic Mass MMMT NA NA
10 1+ 1 NEG Endometrium MMMT NA NA
11 1+ NP NEG Ovary MMMT NA NA
12 0 NP NEG Endometrium ESS NA NA
13 0 NP NEG Endometrium ESS NA NA
14 1+ NP NEG Cervix ECAdCA 1 1
15 0 NP NEG Ovary Yolk Sac
Tumor
NA NA
Bold data signify the positive results
IHC immunohistochemistry score, FISH fluorescence in-situ hybridization HER2/
CEP17 ratio, FIGO FIGO grade, Nuc nuclear grade, NP not performed, POS
positive, NEG negative, UnDiff undifferentiated carcinoma, ECAdCA endocervical
adenocarcinoma, MMMT malignant mixed Müllerian tumor, ESS endometrial
stromal sarcoma, NA not applicable
Table 6 Summary of overall findings including HER2/neu
reactions in the 125 cases
Overall information HER2/neu
Groups Neoplasm Median age n % POS (n) POS (%)
Group I CCCA 54 11 8.8 % 3 27.3 %
Group II SCA 58 45 36.0 % 5 11.1 %
Group III ENAdCA 61.5 28 22.4 % 0 0.0 %
Group IV MxSEAdCA 65 26 20.8 % 1 3.8 %
Group V Other 54 15 12.0 % 1 6.7 %
CCCA clear cell carcinoma, SCA serous carcinoma, ENAdCA endometrioid
adenocarcinoma, MxSEAdCA mixed surface epithelial adenocarcinomas, Other
other neoplasms, POS positive
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in their series where 53 % of which had significant het-
erogeneity of the protein expression by IHC [19]. They
have reported the pattern of the IHC reaction as lack of
apical membrane staining resulting in a lateral/basolateral
reactive pattern [19].
It has been shown that the prevalence of the HER2
positivity in the Asian female population with ovarian
mucinous tumors was 18 % with 100 % concordance rate
between IHC and FISH [10]. In our study none of our
mucinous tumors showed the HER2 overexpression or
amplification.
In endometrial and ovarian carcinomas, as in breast
cancer, there have been several studies showing the
amplification of the HER2 gene is associated with
chemo-resistance and poor prognosis. Transtuzumab
combined with chemotherapy agents is currently be-
ing investigated in clinical trials in some institutions
[28]. In addition to the positive IHC and FISH find-
ings, we have the follow-up for three cases in this
study. Two of the three patients had responded well
to the treatment which makes transtuzumab a prom-
ising therapeutic agent in cases with the HER2 ampli-
fication of the Müllerian organs. Future studies
should include more comprehensive follow ups in re-
lation to the anti-HER2 targeted therapies. In this
series, we only had follow-ups on four patients.
One point of caution is the inclusion criteria for col-
lection of the cases in this series where the selection was
based on the HER2 testing if it had been ordered by the
clinicians or the pathologists on some cases. Therefore,
the results may be somewhat skewed due to the procliv-
ities inherent in the practice of our clinicians and the
routines in our institution. Nevertheless, as mentioned
earlier, our findings are in agreement with other investi-
gators’ findings in relation to serous carcinomas particu-
larly when tumors were broken down based on their
anatomical locations as displayed in Table 7 [19, 21–26].
Despite the bias due to the case selection process, our
findings signify the importance of the HER2 testing in
particular gynelogical cancers.
Conclusions
In conclusion, we recommend performing the HER2
tests on gynecologic carcinomas of clear cell, serous, and
undifferentiated types particularly when they arise in the
endometrium. Since there are some discordant IHC/
FISH results, we also propose performing the HER2 test-
ing by both IHC and FISH assays when IHC score is less
than 3+ as exhibited well by the cases in this series
(Table 2).
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Table 7 Arrangement by the tumor sites in each Group
Primary Site Group I Group II Group III Group IV Group V
CCCA SCA ENAdCA MxSEAdCA Other
n HER2+ n HER2+ n HER2+ n HER2+ n HER2+
Endometrium 6 2 (33.3 %) 9 4 (44.4 %) 22 11 1 (9.1 %) 10 1 (10.0 %)
Ovary 5 1 (20.0 %) 30 1 (3.3 %) 5 13 3
Fallopian Tube 1 1
Peritoneum 5 1
Pelvic Mass 1 1
Cervix 1
All Sites 11 3 (27.3 %) 45 5 (11.1 %) 28 0 (0.0 %) 26 1 (3.9 %) 15 1 (6.7 %)
Bold data signify the positive results
CCCA clear cell carcinoma, SCA serous carcinoma, ENAdCA endometrioid adenocarcinoma, MxSEAdCA mixed surface epithelial adenocarcinoma, Other other
neoplasms, HER2+ positive HER2/neu
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